Browse > Article

Effects of Pioglitazone on Insulin Sensitivity, Ovarian Function and Intraovarian Stromal Blood Flow in Women with Polycystic Ovary Syndrome  

Lee, Hyang-Ah (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Kim, Chung-Hoon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Choi, Jeong-Won (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Park, Sun-Jung (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Lee, Soo-Jeong (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Choi, Eun-Sun (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Kim, Sung-Hoon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Chae, Hee-Dong (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Son, Young-Soo (Department of Obstetrics and Gynecology, College of Medicine, Cheju University)
Kang, Byung-Moon (Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center)
Publication Information
Clinical and Experimental Reproductive Medicine / v.32, no.2, 2005 , pp. 155-164 More about this Journal
Abstract
Objective: This study was performed to investigate the effects of pioglitazone, an insulin sensitizing agent, on insulin resistance, ovarian function and intraovarian stromal blood flow in patients with polycystic ovarian syndrome (PCOS). Material and Methods: Thirty patients with PCOS, aged 18~34 years, were recruited. Criteria for diagnosis of PCOS were as defined in 2003 Rotterdam consensus. They were treated for 6 months with pioglitazone at a dose of 30 mg/day orally. The hormonal blood profile, fasting serum glucose levels, a glycemic response to 75 g oral glucose tolerance test (OGTT), and an ovarian stromal artery (OSA) blood flow were assessed at baseline and after 6 months of treatment. Results: Eighteen (60.0%) of 30 patients treated with pioglitazone demonstrated a spontaneous ovulation After pioglitazone treatment, fasting insulin concentrations, serum glucose levels after 75 g OGTT significantly decreased (p=0.001, p=0.04, respectively), and fasting glucose to insulin (G/I) ratio significantly increased (p<0.001). The pioglitazone treatment induced a significant reduction in serum LH, testosterone (T) and free T levels (p<0.001, p=0.02, p=0.002, respectively). The resistance index (RI) values of OSA significantly increased after treatment (p<0.001). In analyzing pioglitazone-treated patients according to their body mass index (BMI), nonobese group as well as obese group showed a significant improvement in fasting G/I ratio (p<0.01). The pioglitazone treatment induced a significant reduction in serum LH and free T levels in nonobese group (p<0.001, p<0.05, respectively) as well as obese group (p=0.001, p<0.05, respectively). The RI values of OSA significantly increased in both nonobese and obese groups after pioglitazone treatment (p<0.001, p=0.003, respectively). Conclusions: Pioglitazone could ameliorate the glycoinsulinemic metabolism, and this beneficial effects of this drug could improve the endocrine-reproductive condition associated with the decrease of ovarian stromal artery blood flow, in both nonobese and obese patients with PCOS.
Keywords
Pioglitazone; Polycystic ovary syndrome (PCOS); Insulin resistance; Intraovarian stromal blood flow;
Citations & Related Records
연도 인용수 순위
  • Reference
1 De Leo V, la Marca A,Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24: 633-67   DOI   ScienceOn
2 Loverro G, Vicino M, Lorusso F, Vimercati A, Greco P, Selvaggi L. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow. Gynecol Endocrinol 2001; 15: 142-9   DOI   ScienceOn
3 Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18: 1618-25   DOI   ScienceOn
4 Mehta RV, Patel KS, Coffler MS, Dahan, MH, Yoo RY, Archer JS, et al. Luteinizing Hormone Secretion is Not Influenced by Insulin Infusion in Women with Polycystic Ovary Syndrome Despite Improved Insulin Sensitivity During Pioglitazone Treatment. J Clin Endocrinol Metab 2005 (in press)
5 Vrtacnik-Bokal E, Meden-Vrtovec H. Utero-ovarian arterial blood flow and hormonal profile in patients with polycystic ovary syndrome. Hum Reprod 1998; 13: 815-21   DOI   ScienceOn
6 Ortega-Gonzalez C, Luna S, Hernandez L, Crespo, G, Aguayo, P, Arteaga-Troncoso G, et al. Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-resistant Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2005
7 Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527 -34   DOI   ScienceOn
8 Kirchengast S, Huber 1. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255-60   DOI   ScienceOn
9 The Rotterdam ESHRE/ASRM-Sponsored PeOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PeOS). Hum Reprod 2004; 19: 41-7   DOI   ScienceOn
10 Murakawa H, Hasegawa I, Kurabayashi T, Tanaka K. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate. J Reprod Med 1999; 44: 23-7
11 Annos T, Taymor ML. Ovarian pathology associated with insulin resistance and acanthosis nigricans. Obstet Gynecol 1981; 58: 662-4
12 Iuomo MJ, Nestler IE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin NorthAm 2001; 28: 153-64   DOI   ScienceOn
13 Moghetti P, Castello R, Perrone F, Caputo M, Zanolin E, Muggeo M. Metforrnin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 86: 139 -46
14 Iida KT, Kawakami Y, Suzuki M, Shimano, H, Toyoshima, H, Sone, H, et al. Effect of thiazolidinediones and metforrnin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 2003; 284: 1125 -30
15 Ciampelli M, Lanzone A. Insulin and polycystic ovary syndrome: a new look at an old subject. Gynecol Endocrinol 1998; 12: 277-92   DOI   ScienceOn
16 Salehi M, Bravo-Vera R, Sheikh A. Gouller A, Poretsky L. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 2004; 53: 358-76   DOI   ScienceOn
17 Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-93   DOI   ScienceOn
18 Battaglia C, Artini PG, D'Ambrogio G, Genazzani AD, Genazzani AR. The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 1995; 172: 108-13   DOI   ScienceOn
19 Unger JW, Livingston IN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991; 36: 343-62   DOI   ScienceOn
20 Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 2001; 121: 19 -25
21 Battaglia C. The role of ultrasound and Doppler analysis in the diagnosis of polycystic ovary syndrome. Ultrasound Obstet Gynecol 2003; 22: 225 -32   DOI   ScienceOn
22 Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 661-5   DOI   ScienceOn
23 Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835-40   DOI   ScienceOn
24 Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe, R, Ferin M, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003; 88: 4682-8   DOI   ScienceOn